AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00477893
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
Trial: NCT00008242
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00008242
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02494336
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
Trial: NCT00821301
Drug: Fluphenazine HCl
RxNorm normalized name: fluphenazine HCl
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
Trial: NCT03095872
Drug: Vaseline
RxNorm normalized name: Vaseline
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home.
Trial: NCT03095872
Drug: Bepanthen
RxNorm normalized name: Bepanthen
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home.
Trial: NCT03617315
Drug: Hylauronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Schirmer Test, BUT test and OSDI test. Previous and After treatment
Trial: NCT02505191
Drug: St. John's wort prolonged-release tablet 500 mg
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02505191
Drug: St. John's wort film coated tablets 250 mg
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00186446
Drug: bupropion and smoking cessation behavioral intervention
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01937494
Drug: histamine-benzylic alcohol (magistral preparation)
RxNorm normalized name: Benzyl Alcohol
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: passive exposure to histamine during a bronchial hyperresponsiveness challenge
Trial: NCT00894894
Drug: MP-470
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escalating daily doses of amuvatinib
Trial: NCT00894894
Drug: amuvatinib (MP-470)
RxNorm normalized name: 6 MP
DrugBank: Amuvatinib (DB12742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalating doses of daily amuvatinib
Trial: NCT00556478
Drug: PSD502, contains a mixture of lidocaine and prilocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
Trial: NCT00562614
Drug: SLx-2101
RxNorm normalized name: SLx-2101
DrugBank: SLx-2101 (DB05615)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01974843
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
Trial: NCT01974843
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
Trial: NCT00156208
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg Tablet, oral Daily for 18 months
Trial: NCT00156208
Drug: Asoprisnil
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Tablet, oral Daily for 18 months
Trial: NCT04056702
Drug: Elexacaftor-tezacaftor-ivacaftor exposure
RxNorm normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
Trial: NCT03241706
Drug: Low Fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV fructose (1.3 mg/kg/min)
Trial: NCT03241706
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline given as a comparison to fructose.
Trial: NCT03241706
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of somatostatin (60 ng/kg/min)
Trial: NCT03241706
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion of insulin between 20-60 mU/m2/min.
Trial: NCT03241706
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV glucagon (0.65 ng/kg/min).
Trial: NCT03241706
Drug: Dextrose solution
RxNorm normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dextrose to clamp the plasma glucose at the desired level.
Trial: NCT03241706
Drug: High Fructose
RxNorm normalized name: High Fructose Corn Syrup
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV-fructose (6.5 mg/kg/min)
Trial: NCT02955719
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02955719
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01693822
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Trial: NCT02631668
Drug: ferrous succinate and vitamin C
RxNorm normalized name: Ferrous succinate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
Trial: NCT02631668
Drug: ferrous succinate
RxNorm normalized name: Ferrous succinate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
Trial: NCT02631668
Drug: ferrous succinate
RxNorm normalized name: Ferrous succinate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As another active comparator, patients take the tablets of ferrous succinate with double dosage
Trial: NCT01231971
Drug: Florbetapir
RxNorm normalized name: florbetapir
DrugBank: Florbetapir F-18 (DB09149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Trial: NCT01231971
Drug: Flortaucipir
RxNorm normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Trial: NCT02397096
Drug: Doravirine, Tenofovir, Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
Trial: NCT02397096
Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
Trial: NCT02397096
Drug: Baseline regimen of cobicistat-boosted elvitegravir
RxNorm normalized name: cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Trial: NCT02392234
Drug: VX-661/Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed dose combination tablet, oral use
Trial: NCT02392234
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, oral use
Trial: NCT02392234
Drug: Placebo matched to VX-661/ ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed dose combination tablet, oral use
Trial: NCT02392234
Drug: Placebo matched to Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, oral use
Trial: NCT04071106
Drug: Turmeric Extract
RxNorm normalized name: Turmeric Extract
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Trial: NCT04071106
Drug: Turmeric Extract in Olive oil
RxNorm normalized name: Turmeric oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Trial: NCT04071106
Drug: Petrolatum
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Trial: NCT04071106
Drug: calcipotriol/ Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Trial: NCT02313675
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02313675
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00281892
Drug: Fludarabine mono
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa.
Trial: NCT02260024
Drug: Pramipexole IR tablets
RxNorm normalized name: pramipexole Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02260024
Drug: Pramipexole SR C
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02260024
Drug: Pramipexole SR C2
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02260024
Drug: Pramipexole SR C2A
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02260024
Drug: Pramipexole SR C2B
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01181154
Drug: rituximab (Mabthera®)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000 mg at day 1 and day 15
Trial: NCT01634789
Drug: bazedoxifene
RxNorm normalized name: Bazedoxifene
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg oral tablet, single dose
Trial: NCT01634789
Drug: bazedoxifene/conjugated estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg / 0.625 mg oral tablet, single dose
Trial: NCT02052440
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment arm: baclofen 10mg tid
Trial: NCT00697060
Drug: Imexon + docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
Trial: NCT01206972
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
Trial: NCT01206972
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
Trial: NCT01206972
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
Trial: NCT01206972
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
Trial: NCT00306475
Drug: divalproex sodium ER
RxNorm normalized name: Divalproex Sodium ER
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: divalproex sodium ER1000 mg
Trial: NCT02848105
Drug: VPA
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
Trial: NCT00090519
Drug: ruboxistaurin
RxNorm normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg once daily (QD) oral for up to 36 months
Trial: NCT00370942
Drug: GW823093C C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C=25 mg
Trial: NCT03563690
Drug: Celebrex
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
Trial: NCT01183767
Drug: Epigallocatechin-Gallate
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG in a dosage of up to 10mg/kg body weight
Trial: NCT02378649
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
Trial: NCT00171769
Drug: Certoparin
RxNorm normalized name: certoparin
DrugBank: Certoparin (DB09261)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03539952
Drug: Penicillamine (D1-W12)
RxNorm normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillamine during baseline period (D1-W12)
Trial: NCT03539952
Drug: TETA 4HCL (W12-60)
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA 4HCL during post randomisation and 1st extension period (W12-W60)
Trial: NCT03539952
Drug: Penicillamine (W12-W60)
RxNorm normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillamine during rondomisation and 1st extension period period (W12-W60)
Trial: NCT03539952
Drug: TETA 4HCL (60-<W108)
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA 4HCL during 2nd extension period (W60-\<W108)
Trial: NCT02424201
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental
Trial: NCT02424201
Drug: vitamin c
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control
Trial: NCT04094519
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT04094519
Drug: enzalutamide Placebo
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT04094519
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03965949
Drug: Hormone Replacement cycle 1
RxNorm normalized name: adrenocorticotropic hormone 1-24
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
Trial: NCT03965949
Drug: Hormone Replacement cycle 2
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Hormone Replacement cycle with GnRHa suppression
Trial: NCT03301870
Drug: Positive Control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
Trial: NCT03301870
Drug: Negative Control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water for Injection, USP
Trial: NCT00715351
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Trial: NCT03115099
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously
Trial: NCT03115099
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT00259142
Drug: Chloroquine, sulphadoxine-pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02261805
Drug: Ganetespib
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01887275
Drug: conventional interferon-α
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.